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Although the clinical use of streptomycin has declined greatly, it is still a commonly 
used anti-tuberculous drug. Given the re-emergence of tuberculosis and the limited 
number of anti-tuberculous drugs, the use of streptomycin has gained renewed 
interest.  
Streptomycin is administered by deep intramuscular injections and, in both Europe 
and the USA, the manufacturers do not recommend intravenous administration. 
However, repeated intramuscular injections of streptomycin produce pain and 
inflammation. 
In this investigation, we assessed the tolerance and safety of intravenous 
streptomycin, an off-label method of administration that could be clinically useful in 
patients with tuberculosis and other infectious diseases. 
Consecutive patients with tuberculosis who were B50 years old and had normal 
renal function (serum creatinine \1.2 mg/dl) were selected. The study was 
conducted in a university-affiliated hospital from January 2011 to March 2012. This 
study was approved by the local institutional committee of clinical trials. The 
purpose of the study was explained to the patients and those that gave 
written informed consent were included. 
Patients were empirically treated with standard doses of rifampin, isoniazid and 
pyrazinamide. In addition, streptomycin sulphate (Estreptomicina Normon, Madrid, 
Spain) 15 mg/kg/24 h in 100 ml of normal saline was administered 
intravenously over 45–60 min. In some patients with risk factors for multi-resistant 
tuberculosis, ethambutol was also added in the initial empirical regimen. 
Serum levels of streptomycin were measured on the third day of treatment by 
means of ultra-performance liquid chromatography-mass spectrometry 1 h after the 
end of infusion (peak level) and before the next dose (trough 
level), following a protocol previously detailed. 
Patients were examined daily with bedside vestibular and Romberg tests and 
asked for signs of vestibular or cochlear dysfunction. Haematological testing and 
chemistry were recorded at baseline and every other day. Screen for hearing loss 
was assessed by a Rinne and Weber 256-Hz tuning fork at the bedside to avoid 
movements of contagious patients through the hospital. When tests were 
uncertain or responses difficult to reproduce, pure tone audiometry was performed. 
Because the study was designed to assess the tolerance of intravenous 
streptomycin therapy in the short term, we considered a minimum of 1 week of 
administration in order to include patients into the analysis. Basically, streptomycin 
was stopped when rapid, DNA-based, molecular tests to detect mutations 
associated with drug resistance indicated full susceptibility of the infecting strain to 
rifampin and isoniazid, when sputum acid-fast smears were negative or when the 
health-care provider estimated that the patient could be discharged from hospital 
to follow therapy on an outpatient basis. Some of these patients continued 
intramuscular streptomycin therapy for different periods of time. 
 
Twenty-seven patients were given intravenous streptomycin. Four of them received 
another course of streptomycin therapy in subsequent admissions; hence, 31 
courses of streptomycin therapy were finally assessed. Most patients (89 %) were 
men with pulmonary (70 %) or disseminated tuberculosis (30 %). The mean age 
was 36.5 ± 10.5 years. Patients had a diagnosis of tuberculosis-based clinical 
findings, imaging techniques and acidfast smears and/or cultures. Fifty-two percent 
of patients were HIV-positive individuals and 40 % were immigrants from South 
America. Intravenous streptomycin was given from 6 to 23 days (11.1 ± 4.5 days). 
Mean ± standard deviation (SD) peak and trough levels were 39.8 ± 21.6 and 2.0 ± 
0.3 lg/ml, respectively. The 75th percentile was 45.9 and 2.2 lg/ml at peak and 
trough, respectively.  
Patients tolerated intravenous streptomycin without vestibular or cochlear toxicity. 
Three patients developed circumoral paresthesia during or immediately after 
streptomycin infusion that ceased when the rate of infusion was slowed down and 
administering the dose did not take less than 45 min. Serum creatinine levels did 
not change after treatment (0.8 ± 0.2 vs. 0.9 ± 0.3 mg/dl). Changes in hearing 
capacity were not observed. In five patients with uncertain Rinne and Weber tuning 
fork tests, the audiograms did not show significant abnormalities. Phlebitis or fever 
associated with intravenous catheters was not observed. 
Soon after the introduction of streptomycin in clinical practice, the general 
recommendation was made that the antibiotic should be given by intramuscular 
injection or by slow intravenous infusion. However, the association of intravenous 
administration, high serum levels of the drug and an increase in side effects led to 
the decision to recommend intramuscular injection of streptomycin. This belief has 
remained until now and providers do not recommend intravenous administration of 
streptomycin. 
Cochlear and vestibular dysfunction are the main and more severe side effects 
observed during streptomycin therapy. In studies performed to compare the 
incidences of toxicities among patients with tuberculosis receiving different 
aminoglycoside drugs, streptomycin, regardless of the route of administration, was 
less ototoxic than kanamycin or amikacin. In these studies, ototoxicity was not 
associated with the route of administration, but it was associated with older age, 
longer duration of treatment and greater total dose received. Noteworthy, 
streptomycin, considered to be the least nephrotoxic aminoglycoside, 
determined most cases of renal dysfunction, although it was mild and short-lived. 
To the best of our knowledge, only a few cases of tuberculosis and endocarditis 
caused by high-level gentamicin-resistant Enterococcus faecalis have been treated 
with intravenous streptomycin. Peloquin et al. treated a series of 32 patients with 
tuberculosis with intravenous streptomycin and showed that the drug was 
well tolerated when administered daily or thrice-weekly and no more toxic that 
other aminoglycoside drugs. 
In this study, we found that the drug was well tolerated and only paresthesia in and 
around the mouth was noted in a few patients. Serum levels of streptomycin were 
in the range previously reported in patients treated with streptomycin 15 mg/kg per 
day and, noteworthy, trough levels of streptomycin were below the previously 
established toxic threshold. 
 
In the hospital setting, intravenous administration of streptomycin may be helpful 
and a more convenient route for administration, preventing the complications and 
discomfort of repeated intramuscular injections. We believe that intravenous 
administration of streptomycin is safe and well tolerated, and may definitely be 
considered for the treatment of tuberculosis and other infections in the hospitalised 
patient. 
 
